Randomized Controlled Trial of Osmotic-Release Methylphenidate With Cognitive-Behavioral Therapy in Adolescents With Attention-Deficit/Hyperactivity Disorder and Substance Use Disorders

被引:71
作者
Riggs, Paula D. [1 ]
Winhusen, Theresa [2 ]
Davies, Robert D. [1 ]
Leimberger, Jeffrey D.
Mikulich-Gilbertson, Susan [1 ]
Klein, Constance [1 ]
Macdonald, Marilyn [1 ]
Lohman, Michelle [1 ]
Bailey, Genie L. [3 ]
Haynes, Louise [4 ]
Jaffee, William B. [5 ]
Haminton, Nancy
Hodgkins, Candace
Whitmore, Elizabeth [1 ]
Trello-Rishel, Kathlene
Tamm, Leanne
Acosta, Michelle C.
Royer-Malvestuto, Charlotte [6 ]
Subramaniam, Geetha [7 ,8 ]
Fishman, Marc [7 ]
Holmes, Beverly W.
Kaye, Mary Elyse [9 ]
Vargo, Mark A.
Woody, George E. [6 ]
Nunes, Edward V. [10 ,11 ]
Liu, David [12 ]
机构
[1] Univ Colorado Denver, Aurora, CO 80045 USA
[2] Univ Cincinnati, Cincinnati, OH 45221 USA
[3] Brown Univ, Providence, RI 02912 USA
[4] Med Univ S Carolina, Charleston, SC USA
[5] Harvard Univ, Cambridge, MA 02138 USA
[6] Univ Penn, Philadelphia, PA 19104 USA
[7] Johns Hopkins Univ, Baltimore, MD 21218 USA
[8] NIDA, Div Clin Neurosci & Behav Res, NIH, Bethesda, MD USA
[9] Univ Pittsburgh, Pittsburgh, PA 15260 USA
[10] Columbia Univ, New York, NY 10027 USA
[11] New York State Psychiat Inst & Hosp, New York, NY 10032 USA
[12] NIDA, Ctr Clin Trials Network, NIH, Bethesda, MD USA
关键词
osmotic-release methylphenidate; randomized controlled trial; ADHD; substance use disorders; ADULT ADHD; YOUNG-ADULTS; ABUSE; RELIABILITY; ATOMOXETINE; PREVALENCE; VALIDITY; SAMPLE; MISUSE;
D O I
10.1016/j.jaac.2011.06.010
中图分类号
B844 [发展心理学(人类心理学)];
学科分类号
040202 ;
摘要
To evaluate the efficacy and safety of osmotic-release methylphenidate (OROSMPH) compared with placebo for attention-deficit/hyperactivity disorder (ADHD), and the impact on substance treatment outcomes in adolescents concurrently receiving cognitive-behavioral therapy (CBT) for substance use disorders (SUD). Method: This was a 16-week, randomized, controlled, multi-site trial of OROS-MPH + CBT versus placebo + CBT in 303 adolescents (aged 13 through 18 years) meeting DSM-IV diagnostic criteria for ADHD and SUD. Primary outcome measures included the following: for ADHD, clinician-administered ADHD Rating Scale (ADHD-RS), adolescent informant; for substance use, adolescent-reported days of use in the past 28 days. Secondary outcome measures included parent ADHD-RS and weekly urine drug screens (UDS). Results: There were no group differences on reduction in ADHD-RS scores (OROS-MPH: -19.2, 95% confidence interval [CI], -17.1 to -21.2; placebo, -21.2, 95% CI, -19.1 to -23.2) or reduction in days of substance use (OROS-MPH: -5.7 days, 95% Cl, 4.0-7.4; placebo: -5.2 days, 95% CI, 3.5-7.0). Some secondary outcomes favored OROS-MPH, including lower parent ADHD-RS scores at 8 (mean difference = 4.4, 95% CI, 0.8-7.9) and 16 weeks (mean difference =6.9; 95% CI, 2.9-10.9) and more negative UDS in OROS-MPH (mean = 3.8) compared with placebo (mean = 2.8; p =.04). Conclusions: OROS-MPH did not show greater efficacy than placebo for ADHD or on reduction in substance use in adolescents concurrently receiving individual CBT for co-occurring SUD. However, OROS-MPH was relatively well tolerated and was associated with modestly greater clinical improvement on some secondary ADHD and substance outcome measures. Clinical Trial Registration Information Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents with Substance Use Disorders (SUD); http://www.clinicaltrials.gov; NCT00264797. J. Am. Acad. Child Adolesc. Psychiatry, 2011;50(9):903-914.
引用
收藏
页码:903 / 914
页数:12
相关论文
共 39 条
[1]  
Adler L.A., 2009, Journal of ADHD Related Disorders, V1, P63
[2]   The Reliability and Validity of Self- and Investigator Ratings of ADHD in Adults [J].
Adler, Lenard A. ;
Faraone, Stephen V. ;
Spencer, Thomas J. ;
Michelson, David ;
Reimherr, Frederick W. ;
Glatt, Stephen J. ;
Marchant, Barrie K. ;
Biederman, Joseph .
JOURNAL OF ATTENTION DISORDERS, 2008, 11 (06) :711-719
[3]  
Brown H., 1999, Applied mixed models in medicine
[4]  
COTTLER LB, 1989, BRIT J ADDICT, V84, P801
[5]  
DuPaul GJ, 1998, ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation
[6]   Drug treatment outcomes for adolescents with comorbid mental and substance use disorders [J].
Grella, CE ;
Hser, YI ;
Joshi, V ;
Rounds-Bryant, J .
JOURNAL OF NERVOUS AND MENTAL DISEASE, 2001, 189 (06) :384-392
[7]   Sample size estimation for longitudinal designs with attrition: Comparing time-related contrasts between two groups [J].
Hedeker, D ;
Gibbons, RD ;
Waternaux, C .
JOURNAL OF EDUCATIONAL AND BEHAVIORAL STATISTICS, 1999, 24 (01) :70-93
[8]   A SHARPER BONFERRONI PROCEDURE FOR MULTIPLE TESTS OF SIGNIFICANCE [J].
HOCHBERG, Y .
BIOMETRIKA, 1988, 75 (04) :800-802
[9]  
JONES RH, 1993, LONGITUDINAL DATA SE
[10]   Psychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: A population-based, birth cohort study [J].
Katusic, SK ;
Barbaresi, WJ ;
Colligan, RC ;
Weaver, AL ;
Leibson, CL ;
Jacobsen, SJ .
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2005, 15 (05) :764-776